<DOC>
	<DOCNO>NCT01794299</DOCNO>
	<brief_summary>The purpose study determine whether ATIR safe effective reduce transplant-related mortality improve overall survival , infused patient hematologic malignancy follow T-cell depleted stem cell graft relate haploidentical donor .</brief_summary>
	<brief_title>Safety Efficacy Donor T-lymphocytes Depleted ex Vivo Host Alloreactive T-cells ( ATIR ) Patients With Hematologic Malignancy Who Received Hematopoietic Stem Cell Transplantation From Haploidentical Donor</brief_title>
	<detailed_description>Study CR-AIR-007 exploratory , open-label , multicenter study . After sign informed consent , patient receive hematopoietic stem cell transplantation ( HSCT ) relate , haploidentical donor , follow infusion ATIR 28 32 day HSCT ( later require patient 's medical condition ) . Patients receive ATIR single infusion dose 2x10E6 viable T-cells/kg . All patient treat ATIR follow 12 month HSCT . Assessments perform weekly visit day ATIR infusion 8 week ATIR infusion , monthly visit 3 6 month HSCT , every 2 month 6 12 month HSCT , every 6 month 12 24 month HSCT .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<criteria>Any following hematologic malignancy : ) Acute myeloid leukemia ( AML ) first remission highrisk feature second high remission b ) Acute lymphoblastic leukemia ( ALL ) first remission highrisk feature second high remission c ) Myelodysplastic syndrome ( MDS ) : transfusiondependent , intermediate high Revised International Prognostic Scoring System ( IPSSR ) risk group Eligible haploidentical stem cell transplantation accord investigator Availability suitable match related unrelated donor follow donor search In second high remission previous remission last less 6 month Diffusing capacity carbon monoxide ( DLCO ) &lt; 50 % predict Left ventricular ejection fraction &lt; 50 % ( evaluate echocardiogram multiple gated acquisition [ MUGA ] ) Aspartate aminotransferase ( AST ) &gt; 2.5 x upper limit normal ( ULN ) ( CTCAE grade 2 ) Bilirubin &gt; 1.5 x ULN ( CTCAE grade 2 ) Creatinine clearance &lt; 50 mL/min ( calculate measure ) Positive test human immunodeficiency virus ( HIV ) Positive pregnancy test ( woman childbearing age ) Prior allogeneic stem cell transplantation use stem cell match sibling donor , match unrelated donor , haploidentical donor , cord blood donor Prior autologous stem cell transplantation Stay intensive care unit 2 month precede 12 month Estimated probability survive less 3 month Known allergy component ATIR ( e.g. , dimethyl sulfoxide ) Any condition , opinion investigator , make patient ineligible study Donor inclusion criterion Haploidentical family donor 2 3 mismatch HLAA , B and/or DR locus unshared haplotype Male female , age ≥ 16 ≤ 75 year Eligible donation accord transplantation center Donor exclusion criterion Positive viral test HIV1 , HIV2 , hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) , Treponema pallidum , human Tlymphotropic virus ( HTLV ) 1* , HTLV2* , WNV* ( test ) ( * Canadian center ) Positive pregnancy test nursing ( woman childbearing age )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Haploidentical stem cell transplantation</keyword>
	<keyword>Graft-versus-host disease</keyword>
	<keyword>Immune reconstitution</keyword>
	<keyword>Alloreactive T-cells</keyword>
	<keyword>Photodepletion</keyword>
	<keyword>Photodynamic treatment</keyword>
	<keyword>TH9402</keyword>
	<keyword>Transplant-related mortality</keyword>
	<keyword>Hematologic malignancy</keyword>
</DOC>